BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15990304)

  • 1. The molecular basis for coxib inhibition of p38alpha MAP kinase.
    Sperandio da Silva GM; Lima LM; Fraga CA; Sant'Anna CM; Barreiro EJ
    Bioorg Med Chem Lett; 2005 Aug; 15(15):3506-9. PubMed ID: 15990304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin.
    Chun KS; Kim SH; Song YS; Surh YJ
    Carcinogenesis; 2004 May; 25(5):713-22. PubMed ID: 14729583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective COX-2 inhibitor regulates the MAP kinase signaling pathway in human osteoarthritic chondrocytes after induction of nitric oxide.
    Takahashi T; Ogawa Y; Kitaoka K; Tani T; Uemura Y; Taguchi H; Kobayashi T; Seguchi H; Yamamoto H; Yoshida S
    Int J Mol Med; 2005 Feb; 15(2):213-9. PubMed ID: 15647833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
    Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
    Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells.
    Chen TH; Kao YC; Chen BC; Chen CH; Chan P; Lee HM
    Eur J Pharmacol; 2006 Jul; 541(3):138-46. PubMed ID: 16765938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking.
    Ravindra GK; Achaiah G; Sastry GN
    Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Petasites hybridus extracts in vitro inhibit COX-2 and PGE2 release by direct interaction with the enzyme and by preventing p42/44 MAP kinase activation in rat primary microglial cells.
    Fiebich BL; Grozdeva M; Hess S; Hüll M; Danesch U; Bodensieck A; Bauer R
    Planta Med; 2005 Jan; 71(1):12-9. PubMed ID: 15678367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostaglandin E2 induces cyclooxygenase-2 expression in human non-pigmented ciliary epithelial cells through activation of p38 and p42/44 mitogen-activated protein kinases.
    Rösch S; Ramer R; Brune K; Hinz B
    Biochem Biophys Res Commun; 2005 Dec; 338(2):1171-8. PubMed ID: 16256948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of unactivated p38 MAP kinase.
    Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
    Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoteichoic acid-induced nitric oxide synthase expression in RAW 264.7 macrophages is mediated by cyclooxygenase-2, prostaglandin E2, protein kinase A, p38 MAPK, and nuclear factor-kappaB pathways.
    Chang YC; Li PC; Chen BC; Chang MS; Wang JL; Chiu WT; Lin CH
    Cell Signal; 2006 Aug; 18(8):1235-43. PubMed ID: 16289764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P38 MAPK mediates COX-2 gene expression by corticosterone in cardiomyocytes.
    Sun H; Xu B; Inoue H; Chen QM
    Cell Signal; 2008 Nov; 20(11):1952-9. PubMed ID: 18657608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional coupling expression of COX-2 and cPLA2 induced by ATP in rat vascular smooth muscle cells: role of ERK1/2, p38 MAPK, and NF-kappaB.
    Lin CC; Lin WN; Wang WJ; Sun CC; Tung WH; Wang HH; Yang CM
    Cardiovasc Res; 2009 Jun; 82(3):522-31. PubMed ID: 19233864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
    Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
    Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors.
    Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M
    Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
    Xiao Z; Varma S; Xiao YD; Tropsha A
    J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
    Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.
    Ogunwobi OO; Beales IL
    Regul Pept; 2006 Mar; 134(1):1-8. PubMed ID: 16169610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-inflammatory activity of 4-methoxyhonokiol is a function of the inhibition of iNOS and COX-2 expression in RAW 264.7 macrophages via NF-kappaB, JNK and p38 MAPK inactivation.
    Zhou HY; Shin EM; Guo LY; Youn UJ; Bae K; Kang SS; Zou LB; Kim YS
    Eur J Pharmacol; 2008 May; 586(1-3):340-9. PubMed ID: 18378223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease.
    Willette RN; Eybye ME; Olzinski AR; Behm DJ; Aiyar N; Maniscalco K; Bentley RG; Coatney RW; Zhao S; Westfall TD; Doe CP
    J Pharmacol Exp Ther; 2009 Sep; 330(3):964-70. PubMed ID: 19556450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p38 MAP kinase inhibitors: many are made, but few are chosen.
    Dominguez C; Powers DA; Tamayo N
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):421-30. PubMed ID: 16022178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.